In the phase 2 NANT2011-01 trial, levels of circulating tumour DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time.
Adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell RCC.
Practice-oriented digitisation approaches can already be found in many areas of medicine. But does digitisation play a role in medical education? Survey results show: There is still a lot of catching up to do.
Adding abiraterone to ADT plus docetaxel significantly improves PFS in patients who present de novo mCSPC without meaningful added short-term toxicity according to phase 3 PEACE-1 trial.
Phase 3 RELATIVITY-047 trial results validate the efficacy of dual checkpoint blockade shown with the LAG-3 inhibitor relatlimab and nivolumab in advanced melanoma patients.
Analysis of phase 3 trials with atezolizumab in stage IV NSCLC patients shows longer overall survival for those experiencing immune-related AEs.
Analysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment.
Patritumab deruxtecan demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily pretreated, metastatic/locally advanced, EGFR-mutated NSCLC.
After initial results over 5 years ago, long-term follow-up data from 3 clinical trials – CheckMate 067, COLUMBUS, and ABC – show a durable and sustained clinical benefit for patients with melanoma.
First-line treatment of patients with MSI-H/dMMR metastatic colorectal cancer (mCRC) with pembrolizumab improves overall survival, but the prespecified threshold for significance was not reached.
The method is called "Augmented Psychotherapy" and shows how depression can be treated when psychotherapy and psychopharmacology are combined.
The UK notified the WHO of a PCR-confirmed monkeypox case on a patient that lived and worked in Delta State, Nigeria. A second case was confirmed on 31 May 2021.
Polypharmacy in RA is associated with increased disease activity, an increased risk of serious adverse events (AEs), and a decreased treatment response.
The phase 3 OUTBACK trial results do not support the use of adjuvant chemotherapy after chemoradiation in women with locally advanced cervical cancer.
Patients with SLE have an increased risk of developing severe infections compared with non-SLE cases. Moreover, 21% of the mortality in SLE is related to these infections.
A significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer is found after 1 year of adjuvant treatment with olaparib.
Adhering to the healthy Dietary Approaches to Stop Hypertension (DASH) diet decreased the risk of gout in women. This effect was more pronounced in genetically predisposed individuals.
Adding the BCL2 inhibitor venetoclax to endocrine therapy does not improve clinical benefit for ER-positive, HER2-negative, locally advanced/metastatic breast cancer patients.
Risankizumab treatment leads to better-than-placebo signs and symptoms in active PsA patients with inadequate response or intolerance to 1 or 2 biologic therapies or at least one DMARD therapy.
First phase-3 CheckMate 648 study results demonstrate higher first-line treatment OS with nivolumab + ipilimumab, or nivolumab + chemotherapy, versus chemotherapy only.